Harrow (HROW) is back in focus after reporting statistically significant results from a randomized contralateral eye study of its ocular anesthetic IHEEZO in patients receiving same day bilateral intravitreal injections.

The IHEEZO update lands after a mixed run for Harrow, with the share price down 21.2% year to date but showing a 4.99% 1 month and 11.13% 3 month share price return, while the 3 year total shareholder return of 148.92% points to strong longer term momentum.

Scan Harrow alongside other eyecare and healthcare specialists that are showing strong fundamentals and potential momentum by moving through our hand picked list of solid balance sheet and fundamentals (51 results).

Bulls point to Harrow’s IHEEZO data and long term return track record, while bears focus on recent share price weakness and current losses. Do the present numbers lean more toward opportunity or caution as you look at valuation next?

Most Popular Narrative: 42.5% Undervalued

Harrow's most followed valuation narrative places fair value at $68.38 per share, well above the last close of $39.33, which frames the latest IHEEZO data against a backdrop of strong implied upside.

The rapidly growing demand for Harrow's portfolio of specialty ophthalmic drugs, particularly VEVYE, IHEEZO, and TRIESENCE, is positioned to accelerate further as aging populations and increased prevalence of chronic ocular diseases expand the baseline patient pool, supporting sustainable long-term revenue growth.

Want to see why this narrative supports such a large gap between price and fair value. The story leans heavily on revenue expansion, margin uplift, and a future earnings profile that looks very different to today.

The narrative uses a 7.11% discount rate and ties Harrow's future cash generation to analysts' assumptions for faster top line growth and much higher profit margins, then discounts those cash flows back to today to reach the $68.38 estimate. That still leaves a wide gap to the current $39.33 share price, so readers may want to test how sensitive that fair value is to their own views on revenue, earnings and valuation multiples over time.

Result: Fair Value of $68.38 (UNDERVALUED)

However, Harrow’s story could change quickly if heavy reliance on VEVYE, IHEEZO and TRIESENCE meets pricing pressure or if new product launches underperform expectations.

Next Steps

If this mix of optimism and caution around Harrow has you on the fence, act while the data is fresh and stress test the thesis yourself. To see what other investors are optimistic about in the current setup, review the 2 key rewards

Looking for more Harrow investment ideas beyond this story?

Do not stop with Harrow. Take a few minutes now to scan other opportunities with solid data behind them so you are not chasing ideas after the crowd moves.

• Zero in on potential mispricings by reviewing a focused set of companies that screen as attractively valued using the 51 high quality undervalued stocks.
• Prioritise resilience by checking a curated group of companies with stronger balance sheets and fundamentals through the list of solid balance sheet and fundamentals (51 results).
• Hunt for early stage opportunities with quality metrics on your side by scanning the 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.